Guardant Health Receives Regulatory Approval In Japan For Guardant360 CDx As Companion Diagnostic tT ENHERTU For Treatment Of Non-Small Cell Lung Cancer Patients With HER2 Mutations
Portfolio Pulse from Benzinga Newsdesk
Guardant Health has received regulatory approval in Japan for its Guardant360 CDx as a companion diagnostic to ENHERTU for the treatment of non-small cell lung cancer patients with HER2 mutations.
September 05, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's Guardant360 CDx has received regulatory approval in Japan, potentially expanding its market and increasing its revenues.
The approval of Guardant360 CDx in Japan is a significant milestone for Guardant Health as it allows the company to expand its market reach. This could lead to increased sales and revenues, which would likely have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100